Trial of Topical Verapamil in Chronic Rhinosinusitis With Nasal Polyps
Status:
Terminated
Trial end date:
2018-03-26
Target enrollment:
Participant gender:
Summary
Verapamil is an L-type calcium channel blocker(CCB) which has been shown to reduce
inflammation in a variety of tissues. Chronic rhinosinusitis with nasal polyps (CRSwNP) is
characterized by eosinophilic inflammation as well as P-gp overexpression. A previous trial
of oral Verapamil showed preliminary efficacy for the treatment of CRSwNP. The goal of this
study is to evaluate the safety and efficacy of intranasal Verapamil in CRSwNP. The study was
initially approved as a Phase Ib/II, but only the Phase Ib portion was completed as part of
this protocol.